The revenue decline and cash burn underscore the need for U.S. government funding or additional capital. Monitor the EscharEx VALUE trial interim data in Q1 2027 and any resolution of the government funding discussions for the U.S. manufacturing facility.
Drug in focus
MDWD drug pipeline →EscharEx
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.
- Next catalyst
- None dated
What to watchThe next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $12.97entry
- T+1 · 4d ago −0.54%α −0.18% · $12.90
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MediWound reported Q3 2026 revenue of $3.6M, down 33% YoY from $5.4M, and a net loss of $0.46 per share, wider than the consensus EPS estimate of -$0.73. The company's 2026 revenue outlook is uncertain due to ongoing U.S. government funding discussions for a planned manufacturing facility. A $17.25M public offering closed after quarter-end strengthens the balance sheet but adds dilution.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $3.6M, down 33% YoY from $5.4M
- Net loss $0.46 per share vs consensus -$0.73 (beat on EPS)
- Operating loss widened to $8.5M from $6.5M YoY
- Cash burn $28.3M in first nine months; cash fell to $28.4M from $53.6M at year-end 2025
- Closed $17.25M public offering in November 2026, adding 9.2% dilution
- 2026 revenue outlook uncertain due to U.S. government funding discussions
- EscharEx Phase III VALUE trial interim assessment and enrollment completion expected by end of Q1 2027
Financial Impact
Revenue decline of $1.8M YoY (33%) in Q3; cash burn of $28.3M in nine months; $17.25M gross proceeds from offering post-quarter
Risk Factors
- Uncertainty around U.S. government funding for manufacturing facility could delay revenue recognition
- Cash burn rate of ~$3.1M per month may require further capital raises
- EscharEx trial failure risk; interim data expected Q1 2027
- Dilution from recent offering and potential future offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401377 |
Track record
13 reports on MDWD
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +20.80% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $12.90 Now $13.55 +5.04% settles Nov 20
- Nov 12, 20264d ago 6-K Bearish 6/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Viewing Entry $12.97 Now $13.55 −4.47% settles Nov 19
- Nov 5, 202611d ago 6-K Bearish 6/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
- Nov 3, 202613d ago 424B5 Bearish 5/10 Entry $14.20 to $13.82 Now $13.55 +4.58% ▲ +2.68% +1.76% vs SPY
- Sep 22, 20267w ago Press Release Bullish 4/10 Entry $13.95 to $13.80 Now $13.55 −2.87% ▼ −1.08% +0.11% vs SPY
- Jun 2, 202623w ago Insider Cluster Bullish 4/10 Entry $13.76 to $14.30 Now $13.55 −1.53% ▲ +3.92% +6.89% vs SPY
- May 27, 202624w ago Press Release Bearish 5/10 Entry $14.33 to $13.73 Now $13.55 +5.44% ▲ +4.19% +4.66% vs SPY
- May 7, 202627w ago Press Release Neutral 1/10 Entry $17.27 to $16.25 Now $13.55 −21.54% ▼ −5.91% −7.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers